BR112018005494A2 - composto, composição farmacêutica, e, método de tratamento de um paciente com uma doença. - Google Patents

composto, composição farmacêutica, e, método de tratamento de um paciente com uma doença.

Info

Publication number
BR112018005494A2
BR112018005494A2 BR112018005494A BR112018005494A BR112018005494A2 BR 112018005494 A2 BR112018005494 A2 BR 112018005494A2 BR 112018005494 A BR112018005494 A BR 112018005494A BR 112018005494 A BR112018005494 A BR 112018005494A BR 112018005494 A2 BR112018005494 A2 BR 112018005494A2
Authority
BR
Brazil
Prior art keywords
disease
patient
treating
compound
pharmaceutical composition
Prior art date
Application number
BR112018005494A
Other languages
English (en)
Inventor
Voortman Gerrit
Peter KOPER Norbert
Original Assignee
Synthon Biopharmaceuticals Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthon Biopharmaceuticals Bv filed Critical Synthon Biopharmaceuticals Bv
Publication of BR112018005494A2 publication Critical patent/BR112018005494A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes

Abstract

a presente invenção refere-se ao conjugado anticorpo-fármaco (adc) que contém duocarmicina (adc) trastuzumabe vc-seco-duba (syd985) para uso no tratamento de pacientes com câncer positivo para her-ihc 3+ ou her2 ihc 2+/fish refratário a trastuzumabe entansina (t-dm1), particularmente pacientes com câncer de mama refratário a t-dm1.
BR112018005494A 2015-09-22 2016-09-21 composto, composição farmacêutica, e, método de tratamento de um paciente com uma doença. BR112018005494A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP15186258 2015-09-22
EP16158710 2016-03-04
EP16169699 2016-05-13
PCT/EP2016/072464 WO2017050846A1 (en) 2015-09-22 2016-09-21 Syd985 treatment of t-dm1 refractory cancer patients

Publications (1)

Publication Number Publication Date
BR112018005494A2 true BR112018005494A2 (pt) 2018-10-09

Family

ID=57068063

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018005494A BR112018005494A2 (pt) 2015-09-22 2016-09-21 composto, composição farmacêutica, e, método de tratamento de um paciente com uma doença.

Country Status (21)

Country Link
US (1) US10821191B2 (pt)
EP (1) EP3352857B1 (pt)
JP (1) JP6591665B2 (pt)
KR (1) KR20180052761A (pt)
CN (1) CN108025190A (pt)
AU (1) AU2016328461B2 (pt)
BR (1) BR112018005494A2 (pt)
CA (1) CA2996600A1 (pt)
CL (1) CL2018000726A1 (pt)
CY (1) CY1123818T1 (pt)
DK (1) DK3352857T3 (pt)
ES (1) ES2854298T3 (pt)
HR (1) HRP20210418T1 (pt)
HU (1) HUE053614T2 (pt)
LT (1) LT3352857T (pt)
MX (1) MX2018003459A (pt)
MY (1) MY194488A (pt)
PL (1) PL3352857T3 (pt)
RU (1) RU2728101C2 (pt)
WO (1) WO2017050846A1 (pt)
ZA (1) ZA201801022B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3876997T3 (da) * 2018-11-09 2022-09-26 Byondis Bv Filtrerbare duocarmycin-holdige antistof-lægemiddelkonjugatsammensætninger og tilhørende fremgangsmåder
IL293626A (en) * 2019-12-20 2022-08-01 Pfizer Treatment with antibody-drug conjugates specific for the her2 site
JP7455316B2 (ja) * 2021-10-20 2024-03-26 国立研究開発法人産業技術総合研究所 抗ガン剤、抗ガン剤のプロドラッグ、体外でガン細胞を死滅させる方法、ガンの治療方法、及びガンの治療装置

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010003718A (es) * 2007-10-19 2010-04-21 Genentech Inc Anticuerpos anti-tenb2 producidos por ingenieria de cisteina y conjugados de farmaco y anticuerpo.
PL2560645T3 (pl) * 2010-04-21 2017-01-31 Syntarga B.V. Koniugaty analogów CC-1065 i łączników dwufunkcyjnych
SG10201911860VA (en) 2014-01-10 2020-02-27 Synthon Biopharmaceuticals Bv Duocarmycin adcs showing improved in vivo antitumor activity

Also Published As

Publication number Publication date
RU2018114457A3 (pt) 2020-01-31
RU2018114457A (ru) 2019-10-24
CN108025190A (zh) 2018-05-11
ZA201801022B (en) 2021-05-26
PL3352857T3 (pl) 2021-08-02
DK3352857T3 (da) 2021-03-01
KR20180052761A (ko) 2018-05-18
WO2017050846A1 (en) 2017-03-30
US20180280533A1 (en) 2018-10-04
MX2018003459A (es) 2018-06-06
CY1123818T1 (el) 2022-05-27
EP3352857A1 (en) 2018-08-01
LT3352857T (lt) 2021-02-25
CA2996600A1 (en) 2017-03-30
AU2016328461B2 (en) 2021-04-08
US10821191B2 (en) 2020-11-03
EP3352857B1 (en) 2021-01-13
AU2016328461A1 (en) 2018-02-22
JP2018527402A (ja) 2018-09-20
JP6591665B2 (ja) 2019-10-16
CL2018000726A1 (es) 2018-06-01
HRP20210418T1 (hr) 2021-04-30
RU2728101C2 (ru) 2020-07-28
MY194488A (en) 2022-11-30
ES2854298T3 (es) 2021-09-21
HUE053614T2 (hu) 2021-07-28

Similar Documents

Publication Publication Date Title
BR112019021822A2 (pt) Terapia de combinação
MA47313B1 (fr) Formulations sous-cutanées d'anticorps her2
ECSP088753A (es) Terapia tumoral con un anticuerpo contra el factor de crecimiento endotelial vascular y un anticuerpo contra el receptor del factor de crecimiento epitelial tipo 2 humano
NZ752526A (en) Pyrrolobenzodiazepine conjugates
PH12018500642A1 (en) Anti-garp antibody
EA201691059A1 (ru) Соединения-пептидомиметики и содержащие их конъюгаты антитело-лекарственное средство
PH12020551043A1 (en) Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
BR112015030377A2 (pt) preparação compreendendo pelo menos um quimioterápico ou substância citotóxica para uso no tratamento de uma doença de um paciente mamífero, preparação e método para tratamento de câncer em um paciente mamífero através de terapia de radiação
SG10201902664RA (en) Combination therapy for treating cancer
ZA201907225B (en) Treatment of her2 positive cancers
EA201791535A1 (ru) Новое соединение 4'-тионуклеозида, а также способ его получения, его фармацевтическая композиция и применение
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
TW201613578A (en) Pharmaceutical combinations
BR112015027474A8 (pt) anticorpo, composição, método de tratamento do paciente que sofre de câncer e uso de um anticorpo.
MX2019003694A (es) Metodos para tratar cancer del tracto biliar.
SG11202011243XA (en) Treatment of her2-mutated cancer by administering anti-her2 antibody-drug conjugate
BR112018005494A2 (pt) composto, composição farmacêutica, e, método de tratamento de um paciente com uma doença.
PH12021551276A1 (en) Combination therapy for the treatment of cancer
MX2022014792A (es) Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican.
BR112017014189A2 (pt) terapia de câncer com um parvovirus combinado com bevacizumabe
BR112016023011A2 (pt) tratamento de câncer gástrico
EA202090741A1 (ru) Конъюгаты антитела к тканевому фактору и лекарственного средства и их применение в лечении рака
BR112018014723A2 (pt) fantasmas bacterianos para o tratamento de câncer
BR112017007364A2 (pt) composição farmacêutica para o uso no tratamento ou prevenção de deficiências de vitaminas e minerais em pacientes que foram submetidos à cirurgia de bypass gástrico
EA201992852A1 (ru) Схема дозирования тезетаксела и капецитабина

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B25F Entry of change of name and/or headquarter and transfer of application, patent and certif. of addition of invention: change of name on requirement

Owner name: SYNTHON BIOPHARMACEUTICALS B.V (NL)

Free format text: A FIM DE ATENDER A ALTERACAO DE NOME REQUERIDA ATRAVES DA PETICAO NO 870200073263, DE 12/06/2020, E NECESSARIO APRESENTAR PROCURACAO COM O NOME ATUAL DA EMPRESA, ALEM DA GUIA DE CUMPRIMENTO DE EXIGENCIA.

B25D Requested change of name of applicant approved

Owner name: BYONDIS B.V. (NL)

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]